Human colon cancer cells surviving high doses of cisplatin or oxaliplatin in vitro are not defective in DNA mismatch repair proteins

Cancer Chemotherapy and Pharmacology

Volumn 49, Issue 6, 2002, Pages 445-452

  Sergent, Catherine ^a   Franco, Noreli ^b   Chapusot, Caroline ^c   Lizard Nacol, Sarab ^a   Isambert, Nicolas ^a   Correia, Maria ^a   Chauffert, Bruno ^a  

^a UNIVERSITÉ DE BOURGOGNE   (France)

^b Centre de Lutte Contre le Cancer GF Leclerc   (France)

^c DIJON UNIVERSITY HOSPITAL   (France)

Author keywords

Cisplatin; Colon cancer; DNA mismatch repair; Drug resistance; Oxaliplatin

Indexed keywords

CISPLATIN; MISMATCH REPAIR PROTEIN PMS2; OXALIPLATIN; PROTEIN; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6; PROTEIN PMS1; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER SURVIVAL; CELL STRAIN CACO 2; CELL STRAIN HT29; CELL SUBPOPULATION; COLON CARCINOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EXPOSURE; DRUG SENSITIVITY; GENE MUTATION; HUMAN; HUMAN CELL; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOSINE TRIPHOSPHATASES; ANTINEOPLASTIC AGENTS; BASE PAIR MISMATCH; BLOTTING, WESTERN; CARRIER PROTEINS; CELL SURVIVAL; CISPLATIN; COLONIC NEOPLASMS; DNA ADDUCTS; DNA PRIMERS; DNA REPAIR; DNA REPAIR ENZYMES; DNA, NEOPLASM; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; FUNGAL PROTEINS; HUMANS; MICROSATELLITE REPEATS; MUTS HOMOLOG 2 PROTEIN; NEOPLASM PROTEINS; NUCLEAR PROTEINS; ORGANOPLATINUM COMPOUNDS; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS; SACCHAROMYCES CEREVISIAE PROTEINS; TUMOR CELLS, CULTURED;

EID: 0036089883     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-002-0450-6     Document Type: Article

References (35)

1. Proteins that specifically recognize cisplatin-damaged DNA: A clue to anticancer activity of cisplatin
2. A phase II study of continuous infusion 5-fluorouracil and leucovorin with weekly cisplatin in metastatic colorectal carcinoma
3. Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in metastatic colorectal cancer
4. The role of DNA mismatch repair in platinum drug resistance
5. Oxaliplatin: A new therapeutic option in colorectal cancer
6. Clinical efficacy of oxaliplatin monotherapy: Phase II trials in advanced colorectal cancer
7. Resistance to cisplatin
8. The role of DNA mismatch repair in drug resistance
9. Analysis of MLH1 and MSH2 expression in ovarian cancer before and after platinum drug-based chemotherapy
10. hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents
11. Decreased cisplatin damage-dependent DNA synthesis in cellular extracts of mismatch repair deficient cells
12. Characterization of MLH1 and MSH2 DNA mismatch repair proteins in cell lines of the NCI anticancer drug screen
13. Microsatellite instability, mismatch repair deficiency, and genetic defects in human cancer cell lines
14. DNA mismatch repair and cancer
15. Genetic instabilities in human cancers
16. Mismatch repair defects in cancer
17. Mismatch repair gene defects in sporadic colorectal cancers with microsatellite instability
18. Dependence on RAD52 and RAD1 for anticancer drug resistance mediated by inactivation of mismatch repair genes
19. Expression of DNA repair proteins hMSH2, hMSH6, hMLH1, O6-methylguanine-DNA methyltransferase and N-methylpurine-DNA glycosylase in melanoma cells with acquired drug resistance
20. Mismatch repair deficiency is associated with resistance to DNA minor groove alkylating agents
21. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: Correlation with replicative bypass of platinum-DNA adducts
22. In vitro amplification of DNA by the polymerase chain reaction
23. Spectra of spontaneous mutations at the hprt locus in colorectal carcinoma cell lines defective in mismatch repair
24. Drugs five years later. Cisplatin
25. Oxaliplatin pharmacokinetics during a four-hour infusion
26. Identification of p53 genetic suppressor elements which confer resistance to cisplatin
27. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents
28. Relationship between radiation-induced G1 phase arrest and p53 function in human tumour cells
29. Enterocyte differentiation is compatible with SV40 large T expression and loss of p53 function in human colonic Caco-2 cells. Status of the pRb1 and pRb2 tumor suppressor gene products
30. Induction of p53-independent apoptosis associated with G2M arrest following DNA damage in human colon cancer cell lines
31. The frequency of hereditary defective mismatch repair in a prospective series of unselected colorectal carcinomas
32. DNA mismatch repair genes and their association with colorectal cancer
33. Molecular basis of HNPCC: Mutations of MMR genes
34. Microsatellite instability and DNA mismatch repair in human cancer
35. Effect of hMSH6 cDNA expression on the phenotype of mismatch repair-deficient colon cancer cell line HCT15